Curriculum Vitae, Carmen Zegarra, M.D. Carmen Zegarra, M.D. FutureSearch Clinical Trials, L.P Parkcrest Drive, Suite 300 Austin, TX 78731
|
|
- Chloe Winifred Black
- 5 years ago
- Views:
Transcription
1 CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) Fax (208) AFFILIATIONS: Carmen Zegarra, M.D. FutureSearch Clinical Trials, L.P Parkcrest Drive, Suite 300 Austin, TX Brodie Ranch Rehabilitation and Healthcare Center Inpatient Facility 2101 Frate Barker Road Austin, TX, EDUCATION: 2001 Acupuncture Training St. Luke s Hospital, Academy of Pain Research, San Francisco, CA Short Term Psychodynamic Therapy Training New Jersey Institute of Psychodynamic Therapy, Paramus, NJ July 1989 June 1992 Residency Training PGY-II-IV Bergen Pines County Hospital, Paramus, NJ July 1988 June 1989 Residency Training PGY-I Bronx-Lebanon Hospital Center, Bronx, NY Physician Surgeon, M.D. Federico Villarreal National University, Lima, Peru CERTIFICATION: Board Certified Adult Psychiatry American Board of Psychiatry and Neurology - 1 -
2 LICENSURE: Texas Medical License #M8450 New Jersey Medical License #MA55807 New York Medical License # RATER CERTIFIED: ADHD-RS-IV C-SSRS VAS PWC BARS/AIMS/SAS EQ-5D NSA-16 SCID BPRS HAM-A PANSS WRAADS CAADID MADRS PROs CGI-S CDSS MINI PSP CGI-I PROFESSIONAL EXPERIENCE: Investigator, September 2012 Present FutureSearch Clinical Trials, LP, Austin, TX Staff Psychiatrist at PES & Outpatient Services, February 2008 December 2012 Austin Travis County Integral Care (ATCMHMR), Austin, TX Psychiatrist, January 2002 December 2007 Private Practice, Montclair, NJ Medical Director, Outpatient Services, September 1998 January 2008 St. Mary s Hospital, Passaic, NJ Preceptor of Clinical Psychiatry, University of Medical and Dentistry of New Jersey, Newark, NJ Medical Director, Inpatient Services, August 1997 August 1998 St. Mary s Hospital, Passaic, NJ Staff Psychiatrist, August 1993 August 1997 St. Mary s Hospital, Passaic, NJ Staff Psychiatrist, June 1992 June 1993 Jersey City Medical Center, Jersey City, NJ Consultant Psychiatrist, Mental Health Clinic of Passaic, Passaic, NJ Consultant Psychiatrist, Emergency Services, Elizabeth General Medical Center, Elizabeth, NJ - 2 -
3 INVESTIGATOR EXPERIENCE: ADHD Bipolar Disorder Pediatric Anxiety Pediatric Bipolar Disorder Addictions Depression Fibromyalgia Obsessive Compulsive Disorder Schizophrenia and Schizoaffective Disorder CLINICAL TRIAL EXPERIENCE: Addictions A multi-center, multi-region, observational Smoking Cessation study to understand the biological or functional changes related to Smoking Cessation in apparently healthy smokers who are continuously abstinent from smoking for one year A Phase III, multi center, double blind, placebo controlled, randomized withdrawal study to evaluate the maintenance and efficacy of XXX in adults aged with moderate to severe binge eating A Twelve-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study with Follow-up Evaluating the Safety and Efficacy of XXX for Smoking Cessation in Healthy Adolescent Smokers A Phase IV, Randomized, Double Blind, Active and Placebo Controlled, Multicenter Study Evaluating the Neuropsychiatric Safety and Efficacy of 12 weeks XXX and XXX for Smoking Cessation in Subjects with and without a History of Psychiatric Disorders A Phase IV, Randomized, Double Blind, Active And Placebo Controlled Multicenter Study Evaluating The Neuropsychiatric Safety And Efficacy Of 12 Weeks XXX And XXX For Smoking Cessation In Subjects With And Without A History of Psychiatric Disorders A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Doseoptimization Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in Adults Aged Years with Moderate to Severe Binge Eating Disorder A Phase III, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of XXX in the Treatment of Adults with Binge Eating Disorder ADHD Pediatric and Adult A Phase I, Investigational Study to Evaluate Usability of ADHD patch in a Naturalistic Setting and to assess Adhesion of ADHD patch compared to XXX in the Clinic Setting in Children, Adolescents and Adults with ADHD - 3 -
4 A Phase III Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Efficacy and Safety Study of 2 Doses of XXX in Adults with Attention Deficit Hyperactivity Disorder (ADHD) A Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of XXX in adults with Attention Deficit Hyperactivity Disorder (ADHD) An Investigational Study to Evaluate Usability of ADHD patch in a Naturalistic Setting and to assess Adhesion of ADHD patch compared to XXX in the Clinic Setting in Children, Adolescents and Adults with ADHD A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of XXX 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD) A Six-Month Open-Label, Multi-Center Study of the Safety and Efficacy of XXX in Adults and Adolescents with ADHD A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of XXX in Adolescent ADHD Patients A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of XXX in Adult ADHD Patients A Phase II, Randomized, Double-blind, Parallel-group, Multicenter Efficacy and Safety Study of XXX versus Placebo in Adults with Attention Deficit Hyperactivity Disorder (ADHD) A Phase IV Randomized, Double-Blind, Multicenter, Parallel Group, Active-Controlled, Dose- Optimization Safety and Efficacy Study of XXX Compared with XXX with a Placebo Reference Arm, in Adolescents Aged Years with Attention-Deficit/Hyperactivity Disorder (ADHD) Bipolar Disorder Pediatric and Adult A Phase III, 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXX as Maintenance Treatment in Patients with Bipolar I Disorder A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of XXX as Maintenance Treatment in Patients with Bipolar I Disorder A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase II Study to Evaluate the Efficacy and Safety of Once a Day, XXX Tablet for Sublingual Administration XXX in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorder in Adult Patients who are on Lithium and/or Valproate - 4 -
5 Efficacy Safety of 3-Week Fixed-Dose XXX Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept, Phase II Study to Evaluate the Efficacy and Safety of Once a Day, XXX as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar I Disorder in Adult Patients Depression A Randomized, Double-Blind, Placebo-Controlled, Phase IV, Relapse Prevention Study Evaluating the Efficacy and Safety of XXX (5, 10 and 20 mg) in Adults With Major Depressive Disorder A Phase III Open-label Long-term Safety Study of XXX in Pediatric Patients With Major Depressive Disorder A Phase III Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of XXX in Pediatric Patients With Major Depressive Disorder A Phase III Multicenter Study of the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy A Phase III, Efficacy and Safety Study of XXX for the Adjunctive Treatment of Major Depressive Disorder A Phase III, Exploratory, Multicenter, Open-label, Flexible-dose Trial of XXX as an Adjunctive Treatment of Adults with Major Depressive Disorder Who Are in School or at Work An Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of XXX as adjunctive treatment in patients with major depressive disorder with an insufficient response to antidepressant treatment A Phase III Double-blind, Placebo-controlled Study of XXX as Adjunctive Therapy in Major Depressive Disorder A Phase III, Long-Term, Open-Label Study of Safety and Tolerability of XXX as Adjunctive Therapy in Major Depressive Disorder An Exploratory, Multicenter, Open-label, Flexible-dose Trial of XXX as an Adjunctive Treatment of Adults With Major Depressive Disorder and Anxiety Symptoms - 5 -
6 A Double-Blind, Placebo-Controlled, Randomized Add-On Study of XXX for Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy A Phase III, Open-Label Extension Study to Assess the Safety and Tolerability of Treatment With XXX in Patients Who Have Completed Study XXX An Interventional, open-label, long term extension study to evaluate the safety and tolerability of XXX as adjunctive treatment in patients with major depressive disorder A Phase III Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX vs. Placebo in the Treatment of Psychotic Symptoms in Patients with Major Depressive Disorder with Psychotic Features A Phase III, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of XXX in Adolescent Patients With Major Depressive Disorder A Phase III, Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixeddose study to evaluate the efficacy and safety of XXX (1 and 3 mg/ day) as adjunctive treatment in elderly patients with major depressive disorder with an inadequate response to antidepressant treatment A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX in Major Depressive Disorder Fibromyalgia A Phase II,Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of XXX in Subjects with Fibromyalgia Schizophrenia A randomized, double-blind, placebo- and active-controlled, multi-center study to assess the antipsychotic efficacy of XXX in patients with schizophrenia. A Phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of 10 mg, 25 mg, 50 mg, and 100 mg once daily oral administration of XXX during a 12-week treatment period in patients with schizophrenia on stable antipsychotic treatment An Open-Label, Long-Term Safety and Tolerability Study of XXX in the Treatment of Subjects With Schizophrenia - 6 -
7 A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of XXX (90-mg and 120 mg) as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses) and Long term safety, and tolerability of XXX in stable schizophrenia subjects A Phase III, An Exploratory, Multicenter, Open-label, Flexible-dose XXX Trial in Adults with Acute Schizophrenia Associated Cognitive Impairment A 12-Week, Randomized, Phase II, Double-blind, Parallel-group, Study of Two Dose Levels of XXX Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-Optimally Controlled Symptoms of Schizophrenia A Phase II, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Schizophrenia to Mitigate or Prevent XXX -Induced Weight Gain A Phase III, Open Label, Multicenter, Extension of Study XXX to Assess the Long-term Safety and Durability of Effect of XXX in Subjects with Stable Schizophrenia A Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose XXX in Acutely Psychotic Subjects with Schizophrenia Phase III, Interventional, open-label, flexible-dose extension study of XXX in patients with schizophrenia Phase III, Interventional, randomized, double-blind, parallel-group, placebo-controlled, activereference, flexible-dose study of XXX in patients with acute schizophrenia A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia A Phase III Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of XXX using XXX as an Active Control in Subjects Diagnosed with Schizophrenia who completed Protocol XXX A Phase IIIb Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of XXX Compared With Placebo Using XXX A Phase III Multicenter 40-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of XXX as an Adjunctive Pro cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy A Randomized, Double-blind, Placebo-controlled, Parallel, 12 Week, Phase III Study of 2 Doses of XXX or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy - 7 -
8 A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXX in the Acute Treatment of Adults With Schizophrenia Other Indications A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered XXX in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) (with or without Decreased Arousal) A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release XXX for the Treatment of Generalized Anxiety Disorder (GAD) A Phase I, Open-Label, Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: XXX, XXX, XXX, XXX, and XXX A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered XXX in Subjects with Drug- Induced Tardive Dyskinesia An Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose study of XXX as adjunctive treatement to XXX or XXX in adult patients suffering from posttraumatic stress disorder (PTSD) A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of XXX in Combination with Selective Serotonin Receptor Inhibitors in Patients with Obsessive Compulsive Disorder LANGUAGES: Spanish & English Fluent - 8 -
Curriculum Vitae, Lara Goenjian Shirikjian, D.O. Lara Goenjian Shirikjian, D.O. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCurriculum Vitae, Michael J. Downing, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com PROFESSIONAL AFFILIATIONS: Michael
More informationCurriculum Vitae, Conrad O. Beckles, M.S., L.M.H.C., Ph.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Conrado Oscar Beckles,
More informationCurriculum Vitae, Corinna Alisangco Gamez, M.D. Corinna Alisangco Gamez, M.D. Pacific Research Partners, LLC. 901 Clay Street Oakland, CA 94607
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationJennifer M. Lytle, M.D., M.P.H. Clinical Trials of the Rockies 3955 E. Exposition Avenue, Suite 100 Denver, CO Tel.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Jennifer M. Lytle, M.D., M.P.H.
More informationCurriculum Vitae, Corinna A. Gamez, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCurriculum Vitae, David P. Walling, Ph.D. David P. Walling, Ph.D. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationAmy Edmondson Mulroy, MD
Curriculum Vitae Amy Edmondson Mulroy, MD 7940 Floyd Curl Drive, Suite 700 7940 Floyd Curl Drive, Suite 1020 San Antonio, Texas 78229 San Antonio, Texas 78229 EDUCATION 1997 General Adult Psychiatry Internship
More informationCurriculum Vitae, Haig Armen Goenjian, M.D. Haig Armen Goenjian, M.D. Collaborative Neuroscience Network, LLC
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationHoward A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009
CONTACT INFORMATION: Howard A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com Glenn Michael Dempsey, M.D. Albuquerque
More informationCURRICULUM VITAE. Andrea Marraffino, Ph.D.
CURRICULUM VITAE CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (866) 669-0234 Fax (208) 575-3169 Email: clinicaltrials@btheodore.com AFFILIATIONS: Florida Clinical
More informationCurriculum Vitae, Joseph J. Savon, M.D.
CONTACT INFORMATION: Joseph J. Savon, M.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Glenn Michael Dempsey,
More informationCurriculum Vitae, Roberta R. Ball, D.O., M.A., F.A.P.A., F.A.C.N.
CONTACT INFORMATION: Roberta R. Ball, D.O., M.A., F.A.P.A., F.A.C.N. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information:
More informationHoward A. Hassman, D.O. Hassman Research Institute, LLC 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009
CONTACT INFORMATION: Howard A. Hassman, D.O. Hassman Research Institute, LLC 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCurriculum Vitae, Glenn Michael Dempsey, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: Glenn Michael Dempsey,
More information09/84-06/88 BA, Chemistry Robert D. Clark Honors College, University of Oregon, Eugene, OR
CONTACT INFORMATION: Drissana T Tran, M.D. Oregon Center for Clinical Investigations, Inc. 702 Church Street NE Salem, OR 97301 Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916)
More informationCurriculum Vitae, Anand Mehta, M.D. Anand Mehta, M.D. Pacific Research Partners, LLC 1611 Telegraph Avenue, Suite 1550 Oakland, CA 94612
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationCurriculum Vitae, Steven H. Reynolds, D.O. Steven H. Reynolds, D.O. Collaborative Neuroscience Network, LLC.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationChief Operating Officer North Star Medical Research, LLC
CURRICULUM VITAE Joann M. Berenda, AAB Chief Operating Officer North Star Medical Research, LLC 18660 Bagley Road, Building II, Suite 205 Middleburg Heights, OH 44130 Telephone: Fax: email: +01 440 234
More informationCurriculum Vitae, Edward H. Ortiz, M.D.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: FutureSearch Trials
More informationWest Virginia University School of Medicine, Morgantown, West Virginia
MARY CARROLL SHEMO, M.D., D.F.A.P.A. CURRICULUM VITAE Psychiatric Alliance of the Blue Ridge Office: (434) 984-6777 First Floor, Old Ivy Commons, 2496 Old Ivy Road, Suite 400 Fax: (434) 296-1412 22903-4895
More informationDavid B. Weiss, M.D., F.A.P.A. Clinical Trials of the Rockies 3955 E. Exposition Avenue, Suite 100 Denver, CO Tel.
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com EDUCATION: David B. Weiss, M.D., F.A.P.A.
More informationCurriculum Vitae, Ward Jackson Paine, M.D. Ward Jackson Paine, M.D. Exemplar Research, Inc Mileground Road Morgantown, WV 26505
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Ward Jackson Paine,
More informationCurriculum Vitae for: GIL LICHTSHEIN, M.D. Gil Lichtshein, M.D., P.A West Camino Real, Suite 220 Boca Raton, FL 33433
Curriculum Vitae for: GIL LICHTSHEIN, M.D. Gil Lichtshein, M.D., P.A. 7200 West Camino Real, Suite 220 Boca Raton, FL 33433 University of Miami Life Science and Technology Park 1951 NW 7 th Ave, Suite
More informationCURRICULUM VITAE Doctor of Medicine University of Virginia, School of Medicine, Charlottesville, Virginia
CURRICULUM VITAE CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Andrew J.
More information9/16/2016. I would feel comfortable dispensing/prescribing varenicline to a patient with a mental health disorder. Learning Objectives
The Smoking Gun: for Smoking Cessation in Patients with Mental Health Disorders BRENDON HOGAN, PHARMD PGY2 PSYCHIATRIC PHARMACY RESIDENT CTVHCS, TEMPLE, TX 09/23/2016 I would feel comfortable dispensing/prescribing
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of March 25-29, 2013 Website: http://www.hsc.usf.edu/psych/ Newsletter Upcoming Higgins Alcohol and Addictions Visiting Professor Presentation The Morsani
More informationThe Maudsley Prescribing Guidelines in
The Maudsley Prescribing Guidelines in 11th Edition David Taylor Director of Pharmacy and Pathology South London and Maudsley NHS Foundation Trust; Professor King's College London, London, UK Paton Chief
More informationPRESCRIBING GUIDELINES
The Maudsley The South London and Maudsley NHS Foundation Trust & Oxleas NHS Foundation Trust PRESCRIBING GUIDELINES 10th Edition David Taylor Carol Paton Shitij Kapur informa healthcare Contents Authors
More informationDiplomate, American Board of Integrative Holistic Medicine, December 2014
Michael David Banov, M.D. - Curriculum Vitae BOARD CERTIFICATION American Board of Psychiatry and Neurology -Re-certification, September 2006 American Board of Psychiatry and Neurology, February 1995 American
More informationCURRICULUM VITAE. University of Columbia Missouri Department of Psychiatry and Neurology
CURRICULUM VITAE Rubén Bravo Valverde, M.D. Forensic and Geriatric Psychiatrist Centro Especializado de Psiquiatría 1995 Road 2 Suite 1209-1210 Bayamón, Puerto Rico 00959-1201 Telephones: (787) 786-0575/780-3752
More informationClinical Trial Centers Alliance
Clinical Trial Centers Alliance offering specialized expertise to fit the unique needs of each client Bobbie Theodore Alliance Director clinicaltrials@btheodore.com www.clinicaltrialscenters.com Executive
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGoal: To learn about and evaluate the value of various biologically-based methods in the treatment of different forms of psychopathology
Goal: To learn about and evaluate the value of various biologically-based methods in the treatment of different forms of psychopathology The medical model and the search for underlying diseases that produce
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of October 29 November 2, 2012 Website: http://www.hsc.usf.edu/psych/ Newsletter Meetings Thursday 11/01/12 8:00 a.m. Call Center Meeting Resident Lectures:
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of April 15-19, 2013 Website: http://www.hsc.usf.edu/psych/ Newsletter Meetings Thursday 04/18/13 8:00 a.m. Call Center Meeting Resident Lectures: 8:00
More informationCertified Clinical Research Investigator (CCRI). Certification by Association of Clinical Research Professionals (ACRP),
Michael David Banov, M.D. - Curriculum Vitae BOARD CERTIFICATION American Board of Psychiatry and Neurology-Re-certification September 2006 American Board of Psychiatry and Neurology-February 1995 American
More informationMore about The Zucker Hillside Hospital
More about The Zucker Hillside Hospital Inpatient Service The Zucker Hillside Hospital's 228-bed Inpatient Service is divided into general and specialty units. There are approximately 3,800 admissions
More informationPediatric Psychopharmacology
Pediatric Psychopharmacology General issues to consider. Pharmacokinetic differences Availability of Clinical Data Psychiatric Disorders can be common in childhood. Early intervention may prevent disorders
More informationMichael David Banov, M.D. - Curriculum Vitae
Michael David Banov, M.D. - Curriculum Vitae OFFICE LOCATIONS Northwest Behavioral Medicine and Northwest Behavioral Research Center 108 Margaret Avenue Marietta, GA 30060 Phone (770) 422-2009 Fax (770)
More informationEffective Health Care Program
Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Antipsychotics medications are approved by the
More informationCognitive Research Corporation
Cognitive Research Corporation Contract Research Organization offering specialized expertise to fit the unique needs of each client Bobbie Theodore clinicaltrials@alliancesites.com An Alliance of Quality
More informationCurriculum Vitae, Ira David Glick, M.D. Ira David Glick, M.D. Pacific Research Partners, LLC 901 Clay Street Oakland, CA 94607
CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: Collaborative Neuroscience
More informationGeodon for anxiety and depression
When drugs like carbamazepine or cisapride are taken with Geodon, drug interactions can potentially occur. This emedtv page lists other drugs that may lead to Geodon. 8-2-2017 Find a comprehensive guide
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of March 4-8, 2013 Website: http://www.hsc.usf.edu/psych/ Newsletter Upcoming Grand Rounds Presentation The Morsani Center, Rooms 1013 A and B: Thursday,
More informationUnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool
December-18 UnitedHealthcare Community (UHCCP) Louisiana Clinical Program Guidelines Record Supplemental Tool Facility Name: Primary Dx: Member Gender: Member Age: Reviewer Name: Date of Facility Review:
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationScottish Medicines Consortium
Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish
More informationMental Health Current Articles Bulletin - April 2018
Library and Knowledge Services Mental Health Current Articles Bulletin - April 2018 How to Obtain an Article If you would like to request any articles included in this bulletin, or to be put onto the bulletin
More informationCURRICULUM VITAE. (if applicable)
CURRICULUM VITAE ME: Rajinder Shiwach, MD DATE: 28 February 2012 POSITION TITLE: OFFICE ADDRESS: InSite Clinical Research 2000 N. Old Hickory Trail 941 York Drive, Suite 205 1008 York Drive 730 E. Park
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationSTEP THERAPY CRITERIA
DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)
More informationCurriculum Vitae, Elan A. Cohen, Ph.D.
CONTACT INFORMATION: Elan A. Cohen, Ph.D. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationCERTIFICATION EXAMINATION IN CHILD AND ADOLESCENT PSYCHIATRY Content Blueprint (October 17, 2018)
CERTIFICATION EXAMINATION IN CHILD AND ADOLESCENT PSYCHIATRY 2019 Content Blueprint (October 17, 2018) Number of questions: 280 1. Development 13 17% 2. Biological and clinical science 13 17% 3. Psychopathology/Classification
More informationC U R R I C U L U M V I T A E. ADDRESS: 101 The City Dr S, Bld 3, Orange, CA,
C U R R I C U L U M V I T A E 1. PERSONAL DATA NAME: Nisha Warikoo, MD ADDRESS: 101 The City Dr S, Bld 3, Orange, CA, 92868 nwarikoo@uci.edu 2. EDUCATION 07/98-12/03: Byramjee Jeejeebhoy Medical College
More informationWPA template for undergraduate and graduate psychiatric education
WPA template for undergraduate and graduate psychiatric education V. Graduate education: a competency based approach All the competencies elucidated for medical students are relevant to training and educating
More informationPACIFIC RESEARCH NETWORK_ 3003 Fourth Avenue, San Diego, CA * (619) Ph. (619) Fax
PACIFIC RESEARCH NETWORK 3003 Fourth Avenue, San Diego, CA 92103 * (619) 294-4302 Ph. (619) 294-4867 Fax JOHN J. DORIA, M.D. EDUCATION 1958 Medical: Universidad Nationale de Mexico, Mexico, Degree: M.
More informationDEPARTMENT OF PSYCHIATRY. Newsletter
DEPARTMENT OF PSYCHIATRY Office of the Chair - Week of May 21-25, 2012 Website: http://www.hsc.usf.edu/psych/ Newsletter The University of South Florida Department of Psychiatry would like to cordially
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationOpen Translational Science in Schizophrenia. Harvard Catalyst Workshop March 24, 2015
Open Translational Science in Schizophrenia Harvard Catalyst Workshop March 24, 2015 1 Fostering Use of the Janssen Clinical Trial Data The goal of this project is to foster collaborations around Janssen
More informationClinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.
Clinical Policy: (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: 08.01.15 Last Review Date: 02.19 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationPRODUCT INFORMATION TEVATIAPINE XR (quetiapine fumarate)
PRODUCT INFORMATION TEVATIAPINE XR (quetiapine fumarate) NAME OF THE MEDICINE Active ingredient: Quetiapine fumarate Chemical Name: Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin-1-yl] ethoxy)
More informationBrief Notes on the Mental Health of Children and Adolescents
Brief Notes on the Mental Health of Children and Adolescents The future of our country depends on the mental health and strength of our young people. However, many children have mental health problems
More informationMODEL PSYCHOPHARMACOLOGY CURRICULUM
Third Edition MODEL PSYCHOPHARMACOLOGY CURRICULUM For Psychiatric Residency Programs, Training Directors and Teachers of Psychopharmacology VOLUME I By A Committee of the American Society of Clinical Psychopharmacology
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationSurveillance report Published: 26 October 2017 nice.org.uk
Surveillance report 2017 Bipolar disorder: assessment and management (2014) NICE guideline Surveillance report Published: 26 October 2017 nice.org.uk NICE 2017. All rights reserved. Subject to Notice of
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationCurriculum Vitae, Neal Adams, M.D., MPH. Neal Adams, MD, MPH Pacific Research Partners, LLC 1611 Telegraph Avenue Oakland, CA 94612
Neal Adams, MD, MPH Pacific Research Partners, LLC 1611 Telegraph Avenue Oakland, CA 94612 CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Site Liaison Tel. (866) 669-0234 Fax (208)
More informationSouth London and Maudsley NHS Foundation Trust: FY1819 Q2 Performance in Initiating
of First 17/YH/0195 228739 17/YH/0196 228435 17/LO/0987 215947 17/LO/1314 224111 17/WM/0441 224759 17/LO/1867 229005 A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity
More informationQUEPINE XR PRODUCT INFORMATION. Name of the medicine. Description. Pharmacology
QUEPINE XR PRODUCT INFORMATION Name of the medicine Quetiapine fumarate. The chemical name is Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin- 1-yl] ethoxy) ethanol] fumarate. Its structural formula
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-6511694:4.0 Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development Name of Finished Product Name of Active Ingredient Protocol
More informationCHILD & ADOLESCENT PSYCHIATRY ALERTS, VOLUME XV, 2013 INDEX
A acceptance and commitment therapy Posttraumatic Stress, 69 ADHD Adjunctive Fatty Acids, 5 Adjunctive Guanfacine Pharmacokinetics, 27 Amantadine, 21 Atomoxetine, 23 Cancer Risk, 31 CBT for Comorbid Anxiety,
More informationUPDATE April 5, 2006 BRIEFING DOCUMENT. Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder
UPDATE April 5, 2006 BRIEFING DOCUMENT Paroxetine Adult Suicidality Analysis: Major Depressive Disorder and Non- Major Depressive Disorder 1. Introduction Selective serotonin reuptake inhibitors (SSRIs)
More informationGOALS FOR THE PSCYHIATRY CLERKSHIP
GOALS FOR THE PSCYHIATRY CLERKSHIP GOALS - The aim of the core psychiatry clerkship is to expose students to patients with mental illness and to prepare them to provide psychiatric care at a basic level.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.59 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at the
More informationSeroquel XR. quetiapine fumarate APPROVED PRODUCT INFORMATION
Seroquel XR quetiapine fumarate APPROVED PRODUCT INFORMATION NAME OF THE MEDICINE Quetiapine fumarate Chemical Name: Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin-1-yl] ethoxy) ethanol] fumarate.
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationAlberta Alcohol and Drug Abuse Commission. POSITION ON ADDICTION AND MENTAL HEALTH February 2007
Alberta Alcohol and Drug Abuse Commission POSITION ON ADDICTION AND MENTAL HEALTH POSITION The Alberta Alcohol and Drug Abuse Commission (AADAC) recognizes that among clients with addiction problems, there
More informationAPO-QUETIAPINE XR. quetiapine fumarate PRODUCT INFORMATION
APO-QUETIAPINE XR quetiapine fumarate PRODUCT INFORMATION NAME OF THE MEDICINE Quetiapine fumarate Chemical Name: Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin-1-yl] ethoxy) ethanol] fumarate.
More informationSupplementary Methods
Supplementary Materials for Suicidal Behavior During Lithium and Valproate Medication: A Withinindividual Eight Year Prospective Study of 50,000 Patients With Bipolar Disorder Supplementary Methods We
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationPregabalin As A Treatment for Generalized Anxiety Disorder. Ashley Storrs PGY III December 2, 2010
Pregabalin As A Treatment for Generalized Anxiety Disorder Ashley Storrs PGY III December 2, 2010 Background Information Approximately 18.1 percent of American adults 18 years or older have an anxiety
More informationDR HORACIO MARCELO WATMAN
DR HORACIO MARCELO WATMAN Born July 30 th 1961 in Buenos Aires, Argentine. Nationality: Argentinian and Italian (dual nationality) Address: Rambla Exposición 894ta 1ra City of residence and private practice:
More informationHypomania spectrum disorder in adolescence: a 15-year follow-up of non-mood morbidity in adulthood
Päären et al. BMC Psychiatry 2014, 14:9 RESEARCH ARTICLE Open Access Hypomania spectrum disorder in adolescence: a 15-year follow-up of non-mood morbidity in adulthood Aivar Päären 1*, Hannes Bohman 1,
More informationCurriculum Vitae, Michael A. Hassman, D.O.
CONTACT INFORMATION: Michael A. Hassman, D.O. Hassman Research Institute, LLC. 175 Cross Keys Road Centennial Center, Bldg. 300 B Berlin, NJ 08009 Site Selection and Information: Bobbie Theodore, Alliance
More informationSEROQUEL XR. quetiapine fumarate PRODUCT INFORMATION
SEROQUEL XR quetiapine fumarate PRODUCT INFORMATION NAME OF THE MEDICINE Quetiapine fumarate Chemical Name: Bis[2-(2-[4-(dibenzo[b,f][1,4]-thiazepin-11-yl)piperazin-1-yl] ethoxy) ethanol] fumarate. The
More informationPerformance of Initiating Q South London and Maudsley NHS Foundation Trust:
16/LO/1102 177307 The Role of Nitric Oxide in Cognition in Schizophrenia: the NOC study 06/03/2017 22/04/2016 15/08/2016 15/08/2016 08/09/2016 08/09/2016 08/09/2016 Neither 16/LO/1299 200774 The development
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationCurriculum Vitae (updated 10/31/16)
Curriculum Vitae (updated 10/31/16) Mark Anthony Novitsky Jr., MD Certifications: - Board Certified in Adult Psychiatry and Neurology - Board Certified in Child and Adolescent Psychiatry Psychiatric Training:
More information